Moderna’s Covid-19 vaccine sales forecast slashed amidst strong competition
Pharmaceutical Technology
JANUARY 25, 2023
It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. The vaccine first gained Emergency Use Approval in December 2020 in response to the Covid-19 pandemic. As seen in Figure 1, Spikevax annual sales forecasts have dropped by 23% on average between the H1 and H2 2022, GlobalData reports.
Let's personalize your content